In the past decade, the advancement on the treatment targeting mutated Epidermal Growth Factor Receptor (EGFR) and Anaplastic Lymphoma Kinase (ALK) have changed considerably the possibility of therapy for Non Small Cell Lung Cancer (NSCLC) patients. Here, ALK is linked to non-small cell lung carcinoma.